Skip to main content

3 Result(s)

within Li-Qiang Pan Remove this filter

and

  1. Article

    Open Access

    Hetero-modification of TRAIL trimer for improved drug delivery and in vivo antitumor activities

    Poor pharmacokinetics and resistance within some tumor cell lines have been the major obstacles during the preclinical or clinical application of TRAIL (tumor-necrosis-factor (TNF)-related apoptosis-inducing l...

    Li-Qiang Pan, Wen-Bin Zhao, Jun Lai, Ding Ding, **ao-Yue Wei… in Scientific Reports (2015)

    Download PDF (5617 KB) View Article

  2. No Access

    Article

    Preclinical studies of targeted therapies for CD20-positive B lymphoid malignancies by Ofatumumab conjugated with auristatin

    Utilization of antibodies to deliver highly potent cytotoxic agents to corresponding antigen-overexpressed tumor cells is a clinically validated therapeutic strategy. Ofatumumab (OFA, trade name Arzerra) is a ...

    Zhao Hui Li, Qian Zhang, Hai Bin Wang, Ya Nan Zhang, Ding Ding… in Investigational New Drugs (2014)

  3. No Access

    Article

    Engineering and refolding of a novel trimeric fusion protein TRAIL-collagen XVIII NC1

    Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is considered to be a promising anticancer agent because its active form TRAIL trimer is able to induce apoptosis in different tumor cell lines w...

    Li Qiang Pan, Zhang Ming **e, **ao **g Tang… in Applied Microbiology and Biotechnology (2013)